TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000337488
  • Gene Name:FIP1L1
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:NA
  • mRNA Pathway:FIP1L1-PDGFRA signaling pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB00619 (APRD01028, EXPT02967, DB03261)
  • Drug Name:Imatinib
  • Drug Method:down-regulated the gene expression

Disease basic infommation

  • Disease:chronic eosinophilic leukemia
  • Tissue:NA

Other information

  • Title:FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
  • Journal:Verh K Acad Geneeskd Belg
  • Published:2005
  • PubMed ID:16089297
  • Abstract:The identification of the FIP1L1-PDGFRA fusion gene provides a molecular explanation for the pathogenesis of approximately half of the patients with the hypereosinophilic syndrome (HES). A diagnostic test to identify FIP1L1-PDGFRA positive HES cases (subsequently reclassified as chronic eosinophilic leukemia, CEL) is now available. FIP1L1-PDGFR alpha is a novel therapeutic target of the kinase inhibitor imatinib (Glivec, Novartis), which provides the basis for the treatment of these patients with this drug. FIP1L1-PDGFRA positive CEL patients respond very well to imatinib therapy, some of which are remarkable responses with normalization of the blood counts within 2 weeks after start of the therapy. Imatinib is well tolerated with minimal side effects, and most CEL patients respond to low doses of imatinib (100 mg/day), being important for lowering both the cost of therapy and drug related toxicity. All imatinib treated FIP1L1-PDGFRA positive CEL patients achieve hematological and cytogenetic remission, and the majority of patients also achieve a molecular remission with the fusion gene no longer detectable in blood, even by the most sensitive PCR techniques.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3